The Global Rheumatic-Heart Disease Management Industry is expected to reach US$2.04 billion by 2033. From a value of US$1.31 billion in 2023, this represents a consistent growth, indicating a compound annual growth rate (CAGR) of 4.5%.
The continuous advancements in biotechnology and pharmaceuticals, which signal a paradigm shift in the healthcare sector, are credited with this notable rise. The global market for the care of rheumatic heart disease is expected to redefine expectations since it embraces innovation and gives patients hope and better prospects everywhere.
Refine Strategies: Request Your Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16349
Between 0.2% and 0.1% of hospitalized patients have acute pericarditis, and 5% of admissions are due to non-ischemic chest pain. Moreover, cardiovascular diseases account for 17.9 million fatalities worldwide, or 31% of all deaths. Over 75% of deaths in low- and middle-income nations are caused by cardiovascular disease. An further element propelling the market’s growth is the adoption of dual therapy for the treatment of rheumatic heart disease.
Increased alcohol and cigarette usage, lifestyle alterations, and changes in lifestyle are other factors that impact the market for rheumatic heart disease treatments and the rise in cardiovascular disorders. It is projected that low- and middle-income countries will prioritize the prevention and treatment of cardiovascular diseases over the course of the analysis period.
The increase in environmental contamination, which increases the likelihood of viral and fungal infections, is another factor driving the market’s growth. Furthermore, the market is growing as a result of the growth in incidence of rheumatic fever and the government’s rising expenditure on healthcare. Additionally, promising market prospects have been created by the key market participants’ continuous progress in biotechnology and the development of drugs for rheumatic heart disease. Another significant factor that is anticipated to quicken market expansion is the rising prevalence of chronic illnesses including type 2 diabetes and cardiovascular disease.
Key Takeaways from the Global Rheumatic Heart Disease Management Industry Study
- Global Rheumatic-Heart Disease Management Market was valued at US$ 25Bn by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 1%
- By Type, the Valve segment of the market constitutes the bulk of the market with a market share of 46%
- By Application, the Hospitals segment dominates the market with a share of 46%
- From 2023 to 2033, rheumatic heart Disease Management sales are expected to flourish at a CAGR of 5%.
- By 2033, the market value of Rheumatic-Heart Disease Management is expected to reach US$ 04
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16349
An upsurge in financial support to researchers for developing new innovative drugs for treatment of rheumatic fever, coupled with growing geriatric population are expected to fuel the Global Rheumatic Heart Disease Management Industry in the forthcoming years, remarks an FMI analyst.
Competitive Landscape:
Prominent players in the Global Rheumatic Heart Disease Management Industry
- Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, Cipla Inc., Abbott, Merck KGaA, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLC., and Bayer AG, among others.
Recent Developments:
- In September 2019, Medtronic announced the launch of Evolut PRO+, a transcatheter aortic valve replacement (TAVR) system in the U.S.
- In September 2019, Abbott initiated the TRILUMINATE pivotal trial for the evaluation of TriClip, a transcatheter tricuspid valve repair for treating tricuspid regurgitation.
Know More About What the Global Rheumatic Heart Disease Management Industry Report Covers
Future Market Insights offers an unbiased analysis of the global Rheumatic-Heart Disease Management Market, providing historical data for 2018-2022 and forecast statistics from 2023-2033. To understand opportunities in the Rheumatic-Heart Disease Management Market, the market is segmented based on type, and application, across five major regions.
Key Segments Covered in the Global Rheumatic Heart Disease Management Industry Analysis:
Global Rheumatic Heart Disease Management Industry by Type:
- Valve
- Myocarditis
- Pericarditis
Global Rheumatic Heart Disease Management Industry by Application:
- Hospital
- Diagnostic Centre
- Research Centre
Global Rheumatic Heart Disease Management Industry by Region:
- North America
- Europe
- Europe
- Latin America
- Middle East & Africa
Secure Your Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16349
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
